LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Novartis AG

Closed

117.96 0.28

Overview

Share price change

24h

Current

Min

117.25

Max

118.42

Key metrics

By Trading Economics

Income

786M

3.6B

Sales

62M

14B

P/E

Sector Avg

18.292

51.198

EPS

2.28

Dividend yield

3.42

Profit margin

26.476

Employees

75,883

EBITDA

643M

5.8B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-8.5% downside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.42%

2.40%

Market Stats

By TradingEconomics

Market Cap

13B

230B

Previous open

117.68

Previous close

117.96

Technical Score

By Trading Central

Confidence

Bearish Evidence

Novartis AG Chart

Past performance is not a reliable indicator of future results.

Related News

12 May 2025, 09:36 UTC

Major Market Movers

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 Apr 2025, 16:35 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 Apr 2025, 11:55 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 Apr 2025, 11:54 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire Regulus in $1.7 Billion Deal

29 Apr 2025, 07:09 UTC

Earnings

Novartis Lifts Guidance After Profit, Sales Top Views -- Update

29 Apr 2025, 05:36 UTC

Earnings

Novartis Lifts Guidance After Profit, Sales Top Views

2 Jun 2025, 14:17 UTC

Market Talk

Novartis's Pluvicto Delivers Positive Results in Third Late-Stage Trial -- Market Talk

27 May 2025, 12:04 UTC

Acquisitions, Mergers, Takeovers

Correct: Novartis Will Offer $7.00 in Cash Per Share

27 May 2025, 12:01 UTC

Acquisitions, Mergers, Takeovers

Novartis: Offer Will Expire on June 24

27 May 2025, 12:00 UTC

Acquisitions, Mergers, Takeovers

Novartis Will Offer $0.001 Per Share

27 May 2025, 11:59 UTC

Acquisitions, Mergers, Takeovers

Novartis: Offer Is to Acquire All Outstanding Shares of Regulus Therapeutics's Common Stock

27 May 2025, 11:59 UTC

Acquisitions, Mergers, Takeovers

Novartis: Redwood Merger Sub Inc. Is an Indirect Wholly Owned Subsidiary of Novartis

27 May 2025, 11:58 UTC

Acquisitions, Mergers, Takeovers

Novartis: Redwood Merger Sub Inc. Has Commenced a Tender Offer

27 May 2025, 11:57 UTC

Acquisitions, Mergers, Takeovers

Novartis Announces Commencement of Tender Offer to Buy Regulus Therapeutics

12 May 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 May 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

30 Apr 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 Apr 2025, 11:39 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire Regulus in $1.7B Deal

30 Apr 2025, 11:16 UTC

Acquisitions, Mergers, Takeovers

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 Apr 2025, 11:15 UTC

Acquisitions, Mergers, Takeovers

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 Apr 2025, 11:14 UTC

Acquisitions, Mergers, Takeovers

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 Apr 2025, 11:13 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Regulus Therapeutics

29 Apr 2025, 12:34 UTC

Market Talk
Earnings

Novartis Solid Result Shifts Investor Focus to 2H -- Market Talk

29 Apr 2025, 11:54 UTC

Market Talk
Earnings

Correction to Novartis Market Talk

29 Apr 2025, 11:47 UTC

Market Talk
Earnings

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

29 Apr 2025, 10:42 UTC

Market Talk
Earnings

Novartis Surprises With Another Beat & Raise -- Market Talk

29 Apr 2025, 10:16 UTC

Market Talk
Earnings

Novartis's Guidance Lift Reflects Strong Sales -- Market Talk

29 Apr 2025, 05:06 UTC

Earnings

Novartis Had Seen Core Operating Profit to Grow at High Single to Low Double-Digit in 2025 at Constant Currencies

29 Apr 2025, 05:06 UTC

Earnings

Novartis Expects Core Operating Profit to Grow Low Double-Digit in 2025 at Constant Currencies

29 Apr 2025, 05:05 UTC

Earnings

Novartis Had Seen Sales Grow Mid- to High-Single Digit in 2025 at Constant Currencies

Peer Comparison

Price change

Novartis AG Forecast

Price Target

By TipRanks

-8.5% downside

12 Months Forecast

Average 107 USD  -8.5%

High 116 USD

Low 88 USD

Based on 5 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

2

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

N/A / 112.63Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.